648 related articles for article (PubMed ID: 7563150)
1. Incidence of second cancers in patients treated for Hodgkin's disease.
Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
[TBL] [Abstract][Full Text] [Related]
2. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
3. Second cancer among long-term survivors from Hodgkin's disease.
Nyandoto P; Muhonen T; Joensuu H
Int J Radiat Oncol Biol Phys; 1998 Sep; 42(2):373-8. PubMed ID: 9788418
[TBL] [Abstract][Full Text] [Related]
4. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
Swerdlow AJ; Barber JA; Horwich A; Cunningham D; Milan S; Omar RZ
Br J Cancer; 1997; 75(1):116-23. PubMed ID: 9000608
[TBL] [Abstract][Full Text] [Related]
5. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer after treatment of Hodgkin's disease.
Hancock SL; Tucker MA; Hoppe RT
J Natl Cancer Inst; 1993 Jan; 85(1):25-31. PubMed ID: 8416252
[TBL] [Abstract][Full Text] [Related]
7. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment.
Swerdlow AJ; Barber JA; Hudson GV; Cunningham D; Gupta RK; Hancock BW; Horwich A; Lister TA; Linch DC
J Clin Oncol; 2000 Feb; 18(3):498-509. PubMed ID: 10653865
[TBL] [Abstract][Full Text] [Related]
8. Second cancer risk following Hodgkin's disease: a 20-year follow-up study.
van Leeuwen FE; Klokman WJ; Hagenbeek A; Noyon R; van den Belt-Dusebout AW; van Kerkhoff EH; van Heerde P; Somers R
J Clin Oncol; 1994 Feb; 12(2):312-25. PubMed ID: 8113838
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the risk of solid tumor following Hodgkin's disease.
Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
[TBL] [Abstract][Full Text] [Related]
10. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors.
Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M
Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496
[TBL] [Abstract][Full Text] [Related]
11. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome.
Mauch PM; Kalish LA; Marcus KC; Coleman CN; Shulman LN; Krill E; Come S; Silver B; Canellos GP; Tarbell NJ
Blood; 1996 May; 87(9):3625-32. PubMed ID: 8611686
[TBL] [Abstract][Full Text] [Related]
12. Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen?
Dietrich PY; Henry-Amar M; Cosset JM; Bodis S; Bosq J; Hayat M
Blood; 1994 Aug; 84(4):1209-15. PubMed ID: 8049435
[TBL] [Abstract][Full Text] [Related]
13. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
Canellos GP
Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
[TBL] [Abstract][Full Text] [Related]
14. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease.
Chronowski GM; Wilder RB; Levy LB; Atkinson EN; Ha CS; Hagemeister FB; Barista I; Rodriguez MA; Sarris AH; Hess MA; Cabanillas F; Cox JD
Am J Clin Oncol; 2004 Feb; 27(1):73-80. PubMed ID: 14758137
[TBL] [Abstract][Full Text] [Related]
15. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
[TBL] [Abstract][Full Text] [Related]
16. Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
Valagussa P; Santoro A; Fossati-Bellani F; Banfi A; Bonadonna G
J Clin Oncol; 1986 Jun; 4(6):830-7. PubMed ID: 3711960
[TBL] [Abstract][Full Text] [Related]
17. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation.
Swerdlow AJ; Douglas AJ; Hudson GV; Hudson BV; Bennett MH; MacLennan KA
BMJ; 1992 May; 304(6835):1137-43. PubMed ID: 1392790
[TBL] [Abstract][Full Text] [Related]
18. Hodgkin's disease, splenectomy and secondary leukemia.
Centurioni R; Brianzoni F; Leoni P; Danieli G
Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
[No Abstract] [Full Text] [Related]
19. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
[TBL] [Abstract][Full Text] [Related]
20. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.
Swerdlow AJ; Schoemaker MJ; Allerton R; Horwich A; Barber JA; Cunningham D; Lister TA; Rohatiner AZ; Vaughan Hudson G; Williams MV; Linch DC
J Clin Oncol; 2001 Mar; 19(6):1610-8. PubMed ID: 11250989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
